Promising Blood Biomarkers for Clinical Use in Alzheimer’s Disease: A Focused Update

키워드

참고문헌 (78)

1. Wilson MR, "Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity", Mol Biosyst, 4, pp.42~52 (2008)
2. Chen M, "Platelets are the primary source of amyloid beta-peptide in human blood", Biochem Biophys Res Commun, 213, pp.96~103 (1995)
3. Kent SA, "The physiological roles of tau and Aβ : implications for Alzheimer’s disease pathology and therapeutics", Acta Neuropathol, 140, pp.417~447 (2020)
4. Barthélemy NR, "Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease", J Exp Med, 217, pp.e20200861~ (2020)
5. Jack CR Jr, "NIA-AA research framework : toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
6. Cummings J, "The"rights"of precision drug development for Alzheimer’s disease", Alzheimers Res Ther, 11, pp.76~ (2019)
7. Sevigny J, "The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease", Nature, 537, pp.50~56 (2016)
8. "Aducanumab (marketed as Aduhelm) information" (2021)[URL]
9. Hampel H, "Developing the ATX(N)classification for use across the Alzheimer disease continuum", Nat Rev Neurol, 17, pp.580~589 (2021)
10. Koychev I, "Blood-based ATN biomarkers of Alzheimer’s disease : a meta-analysis", J Alzheimers Dis, 79, pp.177~195 (2021)
11. Mattsson N, "CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment", JAMA, 302, pp.385~393 (2009)
12. Mulder C, "Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease", Clin Chem, 56, pp.248~253 (2010)
13. Park SA, "Cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease in South Korea", Alzheimer Dis Assoc Disord, 31, pp.13~18 (2017)
14. Palmqvist S, "Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease", EMBO Mol Med, 11, pp.e11170~ (2019)
15. Olsson B, "CSF and blood biomarkers for the diagnosis of Alzheimer’s disease : a systematic review and meta-analysis", Lancet Neurol, 15, pp.673~684 (2016)
16. Hansson O, "CSF biomarkers of Alzheimer’s disease concord with amyloid-βPET and predict clinical progression : a study of fully automated immunoassays in BioFINDER and ADNI cohorts", Alzheimers Dement, 14, pp.1470~1481 (2018)
17. Kaplow J, "Concordance of Lumipulse cerebrospinal fluid t-tau", Aβ42 ratio with amyloid PET status, 2020, pp.16, 144~152
18. Kuhle J, "Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples : ELISA, electrochemiluminescence immunoassay and Simoa", Clin Chem Lab Med, 54, pp.1655~1661 (2016)
19. Janelidze S, "Head-to-head comparison of 8 plasma amyloid-β 42", 40assays in Alzheimer disease, 2021, pp.78, 1375~1382
20. Mielke MM, "Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau-and amyloid-positron emission tomography", Alzheimers Dement, 14, pp.989~997 (2018)
21. Lue LF, "Advance in plasma AD core biomarker development : current findings from immunomagnetic reductionbased SQUID technology", Neurol Ther, 8(Suppl 2), pp.95~111 (2019)
22. "Taiwan FDA approves MagQu plasma Aβ and tau tests" (2021)[URL]
23. Portelius E, "Proteomic studies of cerebrospinal fluid biomarkers of Alzheimer’s disease : an update", Expert Rev Proteomics, 14, pp.1007~1020 (2017)
24. Nakamura A, "High performance plasma amyloid-β biomarkers for Alzheimer’s disease", Nature, 554, pp.249~254 (2018)
25. Ovod V, "Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis", Alzheimers Dement, 13, pp.841~849 (2017)
26. "Plasma Aβ test wins approval—Are p-tau tests far behind?" (2020)[URL]
27. An SSA, "Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ42", Alzheimers Res Ther, 9, pp.86~ (2017)
28. Wang MJ, "Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer’s disease", Alzheimers Res Ther, 9, pp.98~ (2017)
29. Babapour Mofrad R, "Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status", Alzheimers Res Ther, 13, pp.133~ (2021)
30. Keshavan A, "Population-based blood screening for preclinical Alzheimer’s disease in a British birth cohort at age 70", Brain, 144, pp.434~449 (2021)
31. Hyman BT, "National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease", Alzheimers Dement, 8, pp.1~13 (2012)
32. Fagan AM, "Cerebrospinal fluid tau", beta-amyloid(42)ratio as a prediction of cognitive decline in nondemented older adults, 2007, pp.64, 343~349
33. Rowe CC, "Brain amyloid imaging", J Nucl Med, 52, pp.1733~1740 (2011)
34. Chouraki V, "Plasma amyloid-β and risk of Alzheimer’s disease in the Framingham Heart Study", Alzheimers Dement, 11, pp.249~257 (2015)
35. Hansson O, "Evaluation of plasma Abeta(40)and Abeta(42)as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment", Neurobiol Aging, 31, pp.357~367 (2010)
36. Toledo JB, "Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI", Acta Neuropathol, 122, pp.401~413 (2011)
37. Kim HJ, "Elevation of the plasma Aβ40", Aβ42 ratio as a diagnostic marker of sporadic earlyonset Alzheimer’s disease, 2015, pp.48, 1043~1050
38. Jansen WJ, "Prevalence of cerebral amyloid pathology in persons without dementia : a meta-analysis", JAMA, 313, pp.1924~1938 (2015)
39. Serrano-Pozo A, "Mild to moderate Alzheimer dementia with insufficient neuropathological changes", Ann Neurol, 75, pp.597~601 (2014)
40. Schindler SE, "High-precision plasma β-amyloid 42", 40 predicts current and future brain amyloidosis, 2019, pp.93, e1647~e1659
41. Janelidze S, "Plasma β-amyloid in Alzheimer’s disease and vascular disease", Sci Rep, 6, pp.26801~ (2016)
42. Chiu MJ, "Nanoparticlebased immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer’s disease-A crossvalidation study", Nanomedicine, 28, pp.102182~ (2020)
43. Blennow K, "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease", Nat Rev Neurol, 6, pp.131~144 (2010)
44. Teunissen CE, "Plasma amyloid-β(Aβ 42)correlates with cerebrospinal fluid Aβ42 in Alzheimer’s disease", J Alzheimers Dis, 62, pp.1857~1863 (2018)
45. Janelidze S, "Plasma P-tau181 in Alzheimer’s disease : relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia", Nat Med, 26, pp.379~386 (2020)
46. Lantero Rodriguez J, "Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline", Acta Neuropathol, 140, pp.267~278 (2020)
47. Thijssen EH, "Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration : a retrospective diagnostic performance study", Lancet Neurol, 20, pp.739~752 (2021)
48. Mattsson-Carlgren N, "Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease", Brain, 143, pp.3234~3241 (2020)
49. Palmqvist S, "Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders", JAMA, 324, pp.772~781 (2020)
50. Janelidze S, "Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease", JAMA Neurol, 78, pp.149~156 (2021)
51. Palmqvist S, "Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures", Nat Med, 27, pp.1034~1042 (2021)
52. Ashton NJ, "Plasma p-tau231 : a new biomarker for incipient Alzheimer’s disease pathology", Acta Neuropathol, 141, pp.709~724 (2021)
53. Mielke MM, "Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes", JAMA Neurol, 78, pp.1108~1117 (2021)
54. Brickman AM, "Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study", Alzheimers Dement, 17, pp.1353~1364 (2021)
55. Yuan A, "Neurofilament proteins as biomarkers to monitor neurological diseases and the efficacy of therapies", Front Neurosci, 15, pp.689938~ (2021)
56. Alagaratnam J, "Correlation between CSF and blood neurofilament light chain protein : a systematic review and meta-analysis", BMJ Neurol Open, 3, pp.e000143~ (2021)
57. Ashton NJ, "A multicentre validation study of the diagnostic value of plasma neurofilament light", Nat Commun, 12, pp.3400~ (2021)
58. Barro C, "Neurological symptoms and blood neurofilament light levels", Acta Neurol Scand, 144, pp.13~20 (2021)
59. Mattsson N, "Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease", JAMA Neurol, 76, pp.791~799 (2019)
60. Preische O, "Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease", Nat Med, 25, pp.277~283 (2019)
61. Weston PS, "Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease", Alzheimers Res Ther, 11, pp.19~ (2019)
62. Pereira JB, "Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer’s disease", Neurobiol Aging, 58, pp.14~29 (2017)
63. Quiroz YT, "Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer’s disease kindred : a cross-sectional and longitudinal cohort study", Lancet Neurol, 19, pp.513~521 (2020)
64. Xiao Z, "Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease", Alzheimers Res Ther, 13, pp.123~ (2021)
65. 박선아, "New fluid biomarkers tracking non-amyloid-β and non-tau pathology in Alzheimer’s disease", Experimental and Molecular Medicine, 52, pp.1~13 (2020), 생화학분자생물학회[DOI]
66. Pase MP, "Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes", JAMA Neurol, 76, pp.598~606 (2019)
67. Ding X, "Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease : a systematic review and meta-analysis", Transl Neurodegener, 10, pp.10~ (2021)
68. Illán-Gala I, "Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease", Neurology, 96, pp.e671~e683 (2021)
69. Sugarman MA, "A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s disease", Neurobiol Aging, 94, pp.60~70 (2020)
70. Cullen NC, "Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations", Nat Commun, 12, pp.3555~ (2021)
71. Korley FK, "Serum NfL(neurofilament light chain)levels and incident stroke in adults with diabetes mellitus", Stroke, 50, pp.1669~1675 (2019)
72. Akamine S, "Renal function is associated with blood neurofilament light chain level in older adults", Sci Rep, 10, pp.20350~ (2020)
73. Khalil M, "Serum neurofilament light levels in normal aging and their association with morphologic brain changes", Nat Commun, 11, pp.812~ (2020)
74. Boulo S, "First amyloid β1-42 certified reference material for re-calibrating commercial immunoassays", Alzheimers Dement, 16, pp.1493~1503 (2020)
75. Hansson O, "Biomarkers for neurodegenerative diseases", Nat Med, 27, pp.954~963 (2021)
76. Zetterberg H, "Biomarkers for Alzheimer’s disease-preparing for a new era of disease-modifying therapies", Mol Psychiatry, 26, pp.296~308 (2021)
77. Janelidze S, "Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42", Aβ40 and p-tau, 2022, pp.18, 283~293
78. Benedet AL, "Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer’s disease", Brain, 143, pp.3793~3804 (2020)

관련 논문AI추천